Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS1 | P09382 | 10/20 | 0.61 |
| ▸ | LGALS3 | P17931 | 13/20 | 0.48 |
| ▸ | LGALS9 | O00182 | 2/20 | 0.47 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.47 |
| ▸ | LGALS4 | P56470 | 2/20 | 0.47 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29661706 | 1.00 | LGALS1 (0.61) | LGALS1LGALS3LGALS9LGALS8LGALS4 | |
| SCHEMBL24980874 | 1.00 | LGALS1 (0.61) | LGALS1LGALS3LGALS9LGALS8LGALS4 | |
| SCHEMBL29661738 | 0.87 | LGALS3 (0.45) | LGALS1LGALS3LGALS9LGALS8LGALS4 | |
| SCHEMBL21189793 | 0.85 | LGALS3 (0.65) | LGALS1LGALS3LGALS9LGALS8LGALS4 | |
| SCHEMBL21189791 | 0.85 | LGALS3 (0.65) | LGALS1LGALS3LGALS9LGALS8LGALS4 | |
| SCHEMBL24981303 | 0.85 | LGALS1 (0.84) | LGALS1LGALS3LGALS9LGALS8LGALS4 | |
| SCHEMBL24980726 | 0.85 | LGALS1 (0.84) | LGALS1LGALS3LGALS9LGALS8LGALS4 | |
| SCHEMBL29661539 | 0.85 | LGALS1 (0.84) | LGALS1LGALS3LGALS9LGALS8LGALS4 | |
| SCHEMBL22865325 | 0.85 | LGALS1 (0.65) | LGALS1LGALS3LGALS9LGALS8LGALS4 | |
| SCHEMBL24980651 | 0.85 | LGALS1 (0.65) | LGALS1LGALS3LGALS9LGALS8LGALS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230014870-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230014870-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | LGALS1, LGALS3, LGALS2 | LGALS1 1/4885LGALS3 2/4885LGALS9 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.